HomeCompareGLFN vs PFE

GLFN vs PFE: Dividend Comparison 2026

GLFN yields 666666.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GLFN wins by $8.275235618773884e+34M in total portfolio value
10 years
GLFN
GLFN
● Live price
666666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.275235618773884e+34M
Annual income
$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00
Full GLFN calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GLFN vs PFE

📍 GLFN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGLFNPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GLFN + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GLFN pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GLFN
Annual income on $10K today (after 15% tax)
$56,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, GLFN beats the other by $70,318,753,614,835,575,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GLFN + PFE for your $10,000?

GLFN: 50%PFE: 50%
100% PFE50/50100% GLFN
Portfolio after 10yr
$4.137617809386942e+34M
Annual income
$41,363,972,714,609,160,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GLFN
No analyst data
Altman Z
-327.9
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GLFN buys
0
PFE buys
0
No recent congressional trades found for GLFN or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGLFNPFE
Forward yield666666.67%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$8.275235618773884e+34M$49.6K
Annual income after 10y$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$8.275075881065991e+34M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GLFN vs PFE ($10,000, DRIP)

YearGLFN PortfolioGLFN Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$66,677,367$66,666,666.67$9,153$693.39+$66.67MGLFN
2$415,506,651,117$415,435,306,334.37$8,593$849.25+$415506.64MGLFN
3$2,419,908,598,386,268$2,419,464,006,269,573.00$8,336$1,066.78+$2419908598.38MGLFN
4$13,171,697,643,084,456,000$13,169,108,340,884,183,000.00$8,437$1,384.80+$13171697643084.45MGLFN
5$67,004,927,492,790,120,000,000$66,990,833,776,312,020,000,000.00$9,013$1,875.40+$67004927492790120.00MGLFN
6$318,562,277,003,514,840,000,000,000$318,490,581,731,097,560,000,000,000.00$10,306$2,680.72+$318562277003514871808.00MGLFN
7$1,415,484,168,853,553,000,000,000,000,000$1,415,143,307,217,159,200,000,000,000,000.00$12,820$4,101.38+$1.415484168853553e+24MGLFN
8$5,878,130,573,362,507,000,000,000,000,000,000$5,876,616,005,301,833,000,000,000,000,000,000.00$17,673$6,826.70+$5.878130573362507e+27MGLFN
9$22,813,793,009,840,743,000,000,000,000,000,000,000$22,807,503,410,127,248,000,000,000,000,000,000,000.00$27,543$12,591.86+$2.2813793009840744e+31MGLFN
10$82,752,356,187,738,840,000,000,000,000,000,000,000,000$82,727,945,429,218,320,000,000,000,000,000,000,000,000.00$49,560$26,258.71+$8.275235618773884e+34MGLFN

GLFN vs PFE: Complete Analysis 2026

GLFNStock

McHenry Metals Golf Corp. engages in the design, development, and marketing of golf clubs. The company's TourPure product line includes five drivers and six fairway woods. Left-handed versions of the driver were designed in two models and shorter shafts and smaller grips were made available for ladies clubs. The TourPure driver's proprietary Tungsten Power Ring produces launch angles and reduces backspin, resulting in roll and distance down the fairway. Its distribution channels include the industry's retail channel of off-course golf specialty stores and on-course golf shops; on-course product demonstrations; direct response marketing through television infomercials; direct response catalogs; outbound telemarketing; e-commerce through Internet 'e-tailers' and the company's proprietary Web site (www.mchenrymetals.com); and distributors with domestic and international accounts. Its competitors include Callaway Golf Company, TaylorMade-adidas Golf Company, Acushnet, Ping, Wilson, and Spalding. The company is based in Carlsbad, California.

Full GLFN Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GLFN vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GLFN vs SCHDGLFN vs JEPIGLFN vs OGLFN vs KOGLFN vs MAINGLFN vs JNJGLFN vs MRKGLFN vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.